C4 Therapeutics, Inc. — Director's Dealing 2020

Oct 7, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-06

Reporting Person: COHEN ALAIN J (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-06	Common Stock	C	237149	—	Acquired	237149	Indirect
2020-10-06	Common Stock	C	1482183	—	Acquired	1719332	Indirect
2020-10-06	Common Stock	C	2484425	—	Acquired	2484425	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-06	Series Seed Preferred Stock	$	C	2000000	Disposed		Common Stock (237149)	Indirect
2020-10-06	Series A Preferred Stock	$	C	12500000	Disposed		Common Stock (1482183)	Indirect
2020-10-06	Series B Preferred Stock	$	C	20952403	Disposed		Common Stock (2484425)	Indirect

Footnotes

F1: Each share of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock automatically converted into the Issuer's Common Stock on a 8.4335-to-one basis upon the closing of the Issuer's initial public offering on October 6, 2020 and had no expiration date.

F2: Shares held by the Reporting Person as trustee of the Alain J. Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3: Shares held by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures"). The Reporting Person serves as a manager of Cobro Opportunity Fund GP, LLC, the general partner of Cobro Ventures, and may be deemed to exercise voting and investment power over the shares held by Cobro Ventures. The Reporting Person disclaims beneficial ownership of the shares held by Cobro Ventures except to the extent of his pecuniary interest therein.